NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Atea Pharmaceuticals, Inc. (AVIR) Stock Analysis

Atea Pharmaceuticals, Inc. (AVIR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AVIR

$4.08

−$0.38 (−8.62%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVIR with… →

AVIR Key Statistics

As of Oct 21, 2026
Trading
Open
$4.47
Previous Close
$4.47
Day's Range
4.05–4.47
52-Week Range
2.87–6.45
Volume
465.19K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.39
Valuation
Market Cap
$327.24M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.13
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$158.35M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
80.20M
1-Year Return
+24.01%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
307.67K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AVIR closed at $4.08, +24.01% over 1 year.

Atea Pharmaceuticals, Inc. (AVIR) has a market capitalization of $327.24M.

In fiscal 2025, AVIR reported revenue of $0.00.

AVIR Stock Return by Calendar Year

Atea Pharmaceuticals, Inc. (AVIR) return since Oct 2020: what $10,000 became

1 year
$10,000 $12,401
+24.01%
5 years
$10,000 $3,200
−68.00%
Since Oct 2020
$10,000 $1,345
−86.55%

If you had invested $10,000 in Atea Pharmaceuticals, Inc. (AVIR) at the close on October 30, 2020, the earliest close on record here, it would have been worth $1,345 at the close on October 21, 2026: −86.55% in total, −28.53% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+14.29%
2025+6.57%
2024+9.84%
2023−36.59%
2022−46.20%
2021−78.60%
2020 (partial year)+37.71%

As of October 21, 2026.

AVIR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$158.35M—
2024$0.00−$168.39M—
2023$0.00−$135.96M—
2022$0.00−$115.91M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$180.89M−$158.35M—
2024$0.00—−$192.95M−$168.39M—
2023$0.00—−$164.16M−$135.96M—
2022$0.00—−$130.65M−$115.91M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Atea Pharmaceuticals, Inc. (AVIR) at $327.24M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 55 employees.

The 52-week range on file runs from $2.87 to $6.45. The most recent close on file for AVIR is $4.08, dated October 21, 2026. That is −$0.38 (−8.62%) against the previous close. The latest close sits 42.16% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $158.35M. Earnings per share on a trailing basis come to −2.13.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +24.01%. Measured over 5 years, that is −20.38% a year compounded. Beta against the wider market is reported at 0.39. Annualized volatility over the trailing 6 years is 67.18%.

Growth & Income

The record shows no dividend for AVIR.

Across the complete calendar years on file, 2024 returned +9.84% and 2021 returned −78.60%. Of the 5 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +14.29% year to date.

Peer Comparison

Atea Pharmaceuticals, Inc. (AVIR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Atea Pharmaceuticals, Inc. AVIR $327.24M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Atea Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Visit website →